Analysts Set iRadimed Corporation (NASDAQ:IRMD) PT at $120.00

Shares of iRadimed Corporation (NASDAQ:IRMD) have been given an average rating of “Buy” by the five ratings firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $120.00.

IRMD has been the topic of several analyst reports. Freedom Capital upgraded iRadimed to a “strong-buy” rating in a research note on Thursday, April 2nd. Weiss Ratings lowered shares of iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, May 20th.

iRadimed Price Performance

Shares of IRMD stock opened at $97.03 on Thursday. The firm has a market cap of $1.24 billion, a price-to-earnings ratio of 53.02 and a beta of 0.90. iRadimed has a 52-week low of $55.11 and a 52-week high of $107.90. The company’s 50 day moving average is $93.48 and its 200 day moving average is $95.92.

iRadimed (NASDAQ:IRMD) last posted its earnings results on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.03. The company had revenue of $21.98 million during the quarter, compared to analyst estimates of $21.32 million. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. Analysts anticipate that iRadimed will post 1.52 EPS for the current fiscal year.

iRadimed Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, May 29th. Stockholders of record on Friday, May 15th were paid a dividend of $0.20 per share. The ex-dividend date was Friday, May 15th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.8%. iRadimed’s payout ratio is presently 43.72%.

Insiders Place Their Bets

In other news, CEO Roger E. Susi sold 2,500 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $90.60, for a total transaction of $226,500.00. Following the sale, the chief executive officer directly owned 2,162,500 shares of the company’s stock, valued at $195,922,500. The trade was a 0.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 25,000 shares of company stock worth $2,170,753. 34.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On iRadimed

A number of institutional investors have recently modified their holdings of the stock. Farther Finance Advisors LLC increased its holdings in iRadimed by 827.1% in the fourth quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock valued at $43,000 after buying an additional 397 shares in the last quarter. Quarry LP purchased a new stake in shares of iRadimed during the 3rd quarter worth about $40,000. CWM LLC grew its position in shares of iRadimed by 19.5% during the 4th quarter. CWM LLC now owns 657 shares of the medical equipment provider’s stock valued at $64,000 after acquiring an additional 107 shares during the period. Tower Research Capital LLC TRC grew its position in shares of iRadimed by 191.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after acquiring an additional 495 shares during the period. Finally, USA Financial Formulas purchased a new position in shares of iRadimed in the 4th quarter valued at about $82,000. Hedge funds and other institutional investors own 92.34% of the company’s stock.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.